Physician profile
Jude Stenovitch
NPI 1316020795
$1,052.36
in general payments reported to CMS, 2019-2025
17 companies · $15.70 in 2025
The $15.70 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $18.59 · 2023: $379 · 2024: $37.08 · 2025: $15.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $432.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $195.55 | 2019-2023 | Spravato |
| Lundbeck LLC | $164.25 | 2019 | |
| Sunovion Pharmaceuticals INC. | $153.67 | 2019 | |
| Axsome Therapeutics, INC. | $112.59 | 2023-2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $82.26 | 2019-2020 | |
| Alkermes, INC. | $70.05 | 2023 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $42.04 | 2019 | |
| Vanda Pharmaceuticals INC. | $41.41 | 2019 | |
| Lilly USA, LLC | $40.97 | 2019 | |
| Bausch Health US, LLC | $27.36 | 2023 | Wellbutrin, Aplenzin |
| Allergan, INC. | $23.19 | 2019 | |
| Shire North American Group INC | $20.38 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.63 | 2023 | Trintellix |
| Abbvie INC. | $16.31 | 2023 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $15.70 | 2025 | Uzedy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $15.11 | 2019 | |
| Sage Therapeutics, LLC | $14.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jude Stenovitch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.